Skip to main content

Advertisement

Table 2 Association between MSN and claudin7 immunoexpression and the clinical variables

From: Claudin7 and moesin in endometrial Adenocarcinoma; a retrospective study of 265 patients

Variables (group 1 vs group2) MSN Claudin7
  P value Odds Ratio CI P value Odds Ratio CI
Age* 0.206    0.196   
Stage^ 0.29 1.401 0.741-2.664 1 1.033 0.546-1.962
Tumor size^ 0.013 2.305 1.168-4.724 0.759 0.876 0.456-1.673
Lymho-vascular involvement^ 0.098 0.616 0.344-1.096 0.413 1.255 0.707-2.236
Lymph node status 1 1.018 0.47-2.2 0.365 0.685 0.314-1.48
Depth of myometrial invasion^ 0.305 1.323 0.776-2.262 0.442 0.797 0.467-1.358
Grade_FIGO^ < 0.001 2.561 1.501-4.41 < 0.001 0.389 0.226-0.665
Grade_nuclear^ < 0.001 2.557 1.504-4.385 0.001 0.419 0.245-0.711
Subtype# < 0.001 0.311 0.154-0.609 0.002 2.628 1.353-5.253
Recurrence# 0.867 0.935 0.456-1.925 0.309 1.479 0.722-3.061
Recurrence^ 0.867 0.928 0.454-1.903 0.401 1.383 0.678-2.852
Status# 0.567 0.847 0.462-1.554 0.112 1.623 0.885-3.007
Status^ 1 1.015 0.468-2.226 0.278 1.53 0.705-3.386
  1. ^ The P-values by Fisher exact test to test the correlations between the biomarker and the clinical factors.
  2. * The P-value is calculated by the two sample welch t-test
  3. Stage: Group1: stages I and II; Group 2: stages III and IV
  4. Tumor Size: Group 1:< = 2 cm; Group2: > 2 cm
  5. LVI: Group 1:yes; Group2: no
  6. Depth of myometrial invasion: Group1:< = 50; Group2:> 50
  7. Grade: Group1: grade 1 and 2; Group2; grade 3
  8. Subtype#: Group1:CCC & USC; Group 2: Endometrioid; Group3: MMMT
  9. Recurrence#: Group1:yes; Group2:no; Group3:others
  10. Recurrence^: Group1:yes; Group2: no &others
  11. Status#: Group1: ANED; Group2: all others
  12. Status^: Group1:ANED&AWED; Group2: all others
  13. Interprete the Odds Ratio:
  14. > 1, the proportion of p and n biomarkers status in Group 2 is greater than the proportion in Group 1
  15. < 1, the proportion of p and n biomarkers status in Group 1 is greater than the proportion in Group 2